JPWO2024237217A1 - - Google Patents

Info

Publication number
JPWO2024237217A1
JPWO2024237217A1 JP2025520571A JP2025520571A JPWO2024237217A1 JP WO2024237217 A1 JPWO2024237217 A1 JP WO2024237217A1 JP 2025520571 A JP2025520571 A JP 2025520571A JP 2025520571 A JP2025520571 A JP 2025520571A JP WO2024237217 A1 JPWO2024237217 A1 JP WO2024237217A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025520571A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2023/018019 external-priority patent/WO2023219175A1/ja
Application filed filed Critical
Publication of JPWO2024237217A1 publication Critical patent/JPWO2024237217A1/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2025520571A 2023-05-12 2024-05-10 Pending JPWO2024237217A1 (https=)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/JP2023/018019 WO2023219175A1 (ja) 2022-05-13 2023-05-12 炎症性腸疾患(ibd)を治療または診断する方法および組成物
JP2023131537 2023-08-10
PCT/JP2024/017523 WO2024237217A1 (ja) 2023-05-12 2024-05-10 クロストリジオイデス・ディフィシル菌に結合する抗体

Publications (1)

Publication Number Publication Date
JPWO2024237217A1 true JPWO2024237217A1 (https=) 2024-11-21

Family

ID=93519712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025520571A Pending JPWO2024237217A1 (https=) 2023-05-12 2024-05-10

Country Status (5)

Country Link
EP (1) EP4711462A1 (https=)
JP (1) JPWO2024237217A1 (https=)
CN (1) CN121127591A (https=)
TW (1) TW202448925A (https=)
WO (1) WO2024237217A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5916946B2 (ja) * 2013-03-11 2016-05-11 学校法人関西文理総合学園 モノクローナルIgA抗体の製造方法
CA3224497A1 (en) 2021-07-01 2023-01-05 Reiko SHINKURA Antibody binding to clostridium difficile
US20240417450A1 (en) * 2021-07-02 2024-12-19 The University Of Tokyo Monoclonal antibody-containing composition for suppressing clostridium difficile bacteria

Also Published As

Publication number Publication date
EP4711462A1 (en) 2026-03-18
TW202448925A (zh) 2024-12-16
CN121127591A (zh) 2025-12-12
WO2024237217A1 (ja) 2024-11-21

Similar Documents

Publication Publication Date Title
BR102023012440A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR202022009269U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13152U (https=)
BY13159U (https=)
BY13140U (https=)
BY13135U (https=)
BY13137U (https=)
CN307045579S (https=)
BY13141U (https=)
BY13142U (https=)
BY13143U (https=)
BY13144U (https=)
BY13145U (https=)
BY13150U (https=)
BY13151U (https=)
CN307045468S (https=)

Legal Events

Date Code Title Description
AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20260210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260319